Biogen and the desperation of a need for Alzheimer's drugs

Biogen biologics plant in Denmark

Biogen is set to provoke an early pointer of the direction the FDA will take under new Commissioner Stephen Hahn. Having made the shock decision to resurrect aducanumab after it failed a phase 3 futility analysis, Biogen is set to file for FDA approval of the Alzheimer’s disease drug next year.

The submission will be a test of how far Hahn’s FDA is willing to diverge from its established approval standards. Under U.S. law, companies need to show “substantial” evidence of effectiveness to win approval. Biogen will arrive at the FDA with results from one trial that suggest aducanumab is no better than placebo and data from another that link it to improved scores on a dementia scale.

Biogen and some physicians think the overall data set shows aducanumab works. Many analysts are more skeptical, arguing that Biogen’s data, which even its supporters admit are complex, are too weak to constitute “substantial” evidence.

Virtual Event

Virtual Clinical Trials Online

This virtual event will bring together industry experts to discuss the increasing pace of pharmaceutical innovation, the need to maintain data quality and integrity as new technologies are implemented and understand regulatory challenges to ensure compliance.

Under Hahn’s predecessor, the FDA approved drugs on the basis of evidence that many outsiders saw as insubstantial, but those products typically targeted rare diseases. Alzheimer’s is on a different scale entirely. Other companies will be closely watching how Hahn’s FDA handles the chance to finally get a new treatment to Alzheimer’s patients.

Suggested Articles

A new Harvard spinout, i2O Therapeutics, hopes to have people with diabetes reach for a bottle of pills, instead of the syringe.

The U.S. federal government has tapped Philips and GM to manufacture hospital ventilators for critical COVID-19 care.

Takeda and CSL Behring have set up an alliance work on an unbranded treatment made from the plasma of patients who have recovered from COVID-19.